![Michael Grissinger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 2 317 $ in data 30/06/2026
Michael Grissinger is currently Chairman at Kira Biotech Pty Ltd. since 2020, Director at Atrin Pharmaceuticals LLC since 2018, Independent Director at Aprea Therapeutics, Inc. since 2022, Director at Atriva Therapeutics GmbH since 2020, Director at Envisagenics, Inc., Independent Director at Adicet Bio, Inc. starting 2025, Director at NephroDI Therapeutics, Inc., and Director at AnaCardio AB. Former positions include Independent Director at resTORbio, Inc. from 2018 to 2020, Director at Atrin Pharmaceuticals, Inc., Independent Director at Akari Therapeutics Plc from 2018 to 2024, Member-Management Board at Janssen Pharmaceuticals, Inc., and VP & Head-Pharmaceutical Corporate Development at Johnson & Johnson.
Education includes an undergraduate degree from Juniata College and an MBA from Fox School of Business.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 16/06/2026 | 2.889 ( 0,02% ) | 2 317 $ | 30/06/2026 | |
ADICET BIO INC -.--% | 21/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| APREA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/05/2022 |
| ADICET BIO, INC. | Direttore/Membro del Consiglio | 17/04/2025 |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Engages in discovery and development of proprietary medications | Direttore/Membro del Consiglio | 01/11/2018 |
Kira Biotech Pty Ltd.
 Kira Biotech Pty Ltd. BiotechnologyHealth Technology Operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders | Presidente | 30/07/2020 |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Develops anti-tumour medicine | Direttore/Membro del Consiglio | 01/12/2020 |
Envisagenics, Inc.
 Envisagenics, Inc. BiotechnologyHealth Technology Operates biotechnology company that provides artificial intelligence and RNA-splicing analytics for discovery & development of disease specific therapeutics | Direttore/Membro del Consiglio | - |
AnaCardio AB
 AnaCardio AB Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biopharmaceutical company that develops novel drugs to treat heart failure | Direttore/Membro del Consiglio | - |
Nephrodi Therapeutics, Inc.
 Nephrodi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel AMPK activators for kidney diseases | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| AKARI THERAPEUTICS, PLC | Direttore/Membro del Consiglio | 16/12/2024 |
| ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 15 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Health Technology |
Juniata College
 Juniata College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fox School of Business
 Fox School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Engages in discovery and development of proprietary medications | Health Technology |
Akari Therapeutics Plc
 Akari Therapeutics Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapies for autoimmune and inflammatory diseases | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Develops anti-tumour medicine | Health Technology |
Envisagenics, Inc.
Envisagenics, Inc. BiotechnologyHealth Technology Operates biotechnology company that provides artificial intelligence and RNA-splicing analytics for discovery & development of disease specific therapeutics | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Aprea Therapeutics, Inc.
 Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
Kira Biotech Pty Ltd.
Kira Biotech Pty Ltd. BiotechnologyHealth Technology Operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders | Health Technology |
Adicet Bio, Inc.
 Adicet Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development of cell immunotherapies | Health Technology |
Nephrodi Therapeutics, Inc.
Nephrodi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel AMPK activators for kidney diseases | Health Technology |
AnaCardio AB
AnaCardio AB Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biopharmaceutical company that develops novel drugs to treat heart failure | Commercial Services |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
